BioSpace News Archive

GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today released its inaugural Sustainability Report.

Chemomab Therapeutics Ltd. today announced the company will discuss its first quarter 2023 financial results and provide a corporate update on Thursday, May 11, 2023, at 8:00 am Eastern Time.

Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, May 5, 2023 , at 8:30 a.m. ET to discuss a corporate update and financial results for the first quarter 2023.

SciNeuro Pharmaceuticals today announced that SNP318, a novel Lp-PLA2 inhibitor, is advancing into Phase 1 clinical trials in Australia, positioning it for global development.

Gennao Bio today announced the appointment of Christopher Duke, MBA, M.P.H., as chief executive officer, effective immediately.

Intera Oncology ® Inc. will showcase its Intera 3000 HAI pump as a sponsor of the 10th annual Cholangiocarcinoma Foundation Conference April 12 to 15 in Salt Lake City, Utah.

Canopy Biosciences, a Bruker Company, and Enable Medicine, today announced a partnership to provide Enable Medicine’s advanced analysis pipelines for spatial omics data with the Canopy CellScape ™ system for quantitative high-plex spatial biology.

Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced its intention to offer, subject to market and other conditions, $200.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

Microbiotica today announces it has entered into a clinical trial collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA).

Poolbeg Pharma Plc, a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, confirms that the Company’s Annual Report and Accounts for the period ended 31 December 2022 and the notice of Annual General Meeting 2022 have been posted to shareholders.